Dr. Bo Chen, a Ph.D. from the Albert Einstein College of Medicine and an expert in antibody drug discovery and development, has over 20 years of extensive experience in drug development and remarkable track record of entrepreneurial management. He is not only the practitioner but also the leader of developing innovative medicines.

Dr. Chen founded Keymed in 2016 and led the Company to be listed in main board of Hong Kong Stock Exchange in July 2021. Prior to this, he held jobs in leading biopharmaceuticals development at Trellis Bioscience and StemcentRx. Then Dr. Chen successively founded Wuhan Huaxin Kangyuan Biopharma Co., Ltd. and Shanghai Junshi Biosciences Co., Ltd., as the chairman and general manager. He led the invention and development of the first domestically-developed PD-1 antibody toripalimab (Tuoyi) and the first domestically-developed IL-4α humanized monoclonal antibody (Stapokibart Injection) to receive approval in China. The Stapokibart was approved and launched in September 2024. Currently, the clinical research and development of multiple first-in-class antibody drugs led by Dr. Bo Chen are advancing, ranking first in China and among top three in the world .

Dr. Changyu Wang has more than 20 years of experience in biopharmaceutical R & D. Prior to co-founding Keymed, he held senior research and management roles in Chiron, Medarex, Bristol-Myers Squibb, and Pfizer. Dr. Wang led the development of the world's first PD-1 immune checkpoint inhibitor - Nivolumab, which was approved for commercialization in 2014.

Dr. Wang received his Ph.D. in Microbiology and Immunology from the Medical Center, University of Colorado in 1994, and was a post-doctorate fellow at Harvard and MIT. 

Dr. Gang Xu possesses more than 15 years of experience in novel biologics R&D. He previously served as senior scientist in Roche.

Dr. Xu is responsible in leading virto display platform, drug screening and bispecific antibody drug developments. He has published research papers on immune system recognition, antibody display and bispecific antibodies in internationally renowned academic journals such as Nature Immunology and the Proceedings of the National Academy of Sciences of the USA.

Dr. Xu obtained his Ph.D. in immunology from the Peking Union Medical College in 2004, and he was a post-doctorate fellow in immunology at the University of Maryland.

Dr. Qian Jia has over 30 years of experience in the pharmaceutical industry. She previously served as the chief scientist and vice president at North China Pharmaceutical Group New Drug R&D Co., Ltd., and was the head of National Key Laboratory for Antibody Drug Development.

Under her leadership, the North China Pharmaceutical Group was awarded the title of “National Key Laboratory for Antibody Drug Development” by the Ministry of Science and Technology of China.

Dr. Jia was evaluated as a Senior Engineer in Pharmaceutical Engineering in 2004, and she received her Ph.D. in Pathogenic Molecular Biology from the Chinese Center for Disease Control and Prevention in 2006.

Mr. Zhang Yanrong is responsible for the company's financial management, financing activities, commercial operations, business development, and investor relations. He once worked for China International Capital Corporation Limited and participated in the capital operation projects of multiple biopharmaceutical companies, possessing rich experience in investment and financing. Mr. Zhang Yanrong obtained his Master's degree in Finance from the University of Sheffield in the UK in 2011.